» Articles » PMID: 37051638

Heart Failure with Preserved Ejection Fraction Phenogroup Classification Using Machine Learning

Abstract

Aims: Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex syndrome with a poor prognosis. Phenotyping is required to identify subtype-dependent treatment strategies. Phenotypes of Japanese HFpEF patients are not fully elucidated, whose obesity is much less than Western patients. This study aimed to reveal model-based phenomapping using unsupervised machine learning (ML) for HFpEF in Japanese patients.

Methods And Results: We studied 365 patients with HFpEF (left ventricular ejection fraction >50%) as a derivation cohort from the Nara Registry and Analyses for Heart Failure (NARA-HF), which registered patients with hospitalization by acute decompensated HF. We used unsupervised ML with a variational Bayesian-Gaussian mixture model (VBGMM) with common clinical variables. We also performed hierarchical clustering on the derivation cohort. We adopted 230 patients in the Japanese Heart Failure Syndrome with Preserved Ejection Fraction Registry as the validation cohort for VBGMM. The primary endpoint was defined as all-cause death and HF readmission within 5 years. Supervised ML was performed on the composite cohort of derivation and validation. The optimal number of clusters was three because of the probable distribution of VBGMM and the minimum Bayesian information criterion, and we stratified HFpEF into three phenogroups. Phenogroup 1 (n = 125) was older (mean age 78.9 ± 9.1 years) and predominantly male (57.6%), with the worst kidney function (mean estimated glomerular filtration rate 28.5 ± 9.7 mL/min/1.73 m ) and a high incidence of atherosclerotic factor. Phenogroup 2 (n = 200) had older individuals (mean age 78.8 ± 9.7 years), the lowest body mass index (BMI; 22.78 ± 3.94), and the highest incidence of women (57.5%) and atrial fibrillation (56.5%). Phenogroup 3 (n = 40) was the youngest (mean age 63.5 ± 11.2) and predominantly male (63.5 ± 11.2), with the highest BMI (27.46 ± 5.85) and a high incidence of left ventricular hypertrophy. We characterized these three phenogroups as atherosclerosis and chronic kidney disease, atrial fibrillation, and younger and left ventricular hypertrophy groups, respectively. At the primary endpoint, Phenogroup 1 demonstrated the worst prognosis (Phenogroups 1-3: 72.0% vs. 58.5% vs. 45%, P = 0.0036). We also successfully classified a derivation cohort into three similar phenogroups using VBGMM. Hierarchical and supervised clustering successfully showed the reproducibility of the three phenogroups.

Conclusions: ML could successfully stratify Japanese HFpEF patients into three phenogroups (atherosclerosis and chronic kidney disease, atrial fibrillation, and younger and left ventricular hypertrophy groups).

Citing Articles

Machine learning in predicting heart failure survival: a review of current models and future prospects.

Kokori E, Patel R, Olatunji G, Ukoaka B, Abraham I, Ajekiigbe V Heart Fail Rev. 2024; 30(2):431-442.

PMID: 39656330 DOI: 10.1007/s10741-024-10474-y.


Staging Heart Failure with Preserved Ejection Fraction by Assessing Cardiac Chamber Involvement.

Shchendrygina A, Giverts I, Tokmakova M, Kharchenko E, Vlasova A, Rogova A Eur Cardiol. 2024; 19:e20.

PMID: 39588252 PMC: 11588106. DOI: 10.15420/ecr.2024.31.


Construction of machine learning diagnostic models for cardiovascular pan-disease based on blood routine and biochemical detection data.

Wang Z, Gu Y, Huang L, Liu S, Chen Q, Yang Y Cardiovasc Diabetol. 2024; 23(1):351.

PMID: 39342281 PMC: 11439295. DOI: 10.1186/s12933-024-02439-0.


Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction.

Palazzuoli A, Severino P, DAmato A, Myftari V, Tricarico L, Correale M Rev Cardiovasc Med. 2024; 25(7):270.

PMID: 39139408 PMC: 11317327. DOI: 10.31083/j.rcm2507270.


Clinical phenotypes of heart failure patients with supranormal ejection fraction.

Huang L, Feng J, Zhai M, Huang Y, Zhou Q, Zhang Y ESC Heart Fail. 2024; 11(6):4160-4171.

PMID: 39135272 PMC: 11631309. DOI: 10.1002/ehf2.15021.


References
1.
McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With.... Eur Heart J. 2021; 42(48):4901. DOI: 10.1093/eurheartj/ehab670. View

2.
Kyodo A, Kanaoka K, Keshi A, Nogi M, Nogi K, Ishihara S . Heart failure with preserved ejection fraction phenogroup classification using machine learning. ESC Heart Fail. 2023; 10(3):2019-2030. PMC: 10192264. DOI: 10.1002/ehf2.14368. View

3.
Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

4.
Akao M, Chun Y, Wada H, Esato M, Hashimoto T, Abe M . Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol. 2013; 61(4):260-6. DOI: 10.1016/j.jjcc.2012.12.002. View

5.
Hahn V, Knutsdottir H, Luo X, Bedi K, Margulies K, Haldar S . Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. Circulation. 2020; 143(2):120-134. PMC: 7856095. DOI: 10.1161/CIRCULATIONAHA.120.050498. View